|
| Thursday, January 12, 2017 |
|
|
Eisai to Launch Medication Administration Support Device |
| Eisai Co., Ltd. has announced that the medication administration support device e-OKUSURI-SAN will be launched today for sale to pharmacies, medical institutions and caregiving facilities in Japan. more info >> |
|
| Thursday, January 5, 2017 |
|
|
Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin |
| Eisai Co., Ltd. announced today that, in association with its U.S. pharmaceutical subsidiary Eisai Inc., it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November 2013 marketing and supply agreement it concluded with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, for the chronic weight management treatment lorcaserin hydrochloride. more info >> |
|
| Thursday, December 22, 2016 |
|
|
Eisai and Keio University to Establish a New Industry-Academia Collaboration Site |
| Eisai Co., Ltd. and Keio University announced today that they have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. more info >> |
|
| Tuesday, December 20, 2016 |
|
|
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM (generic name: bendamustine hydrochloride) has been approved in Japan for an additional indication as first-line treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma (MCL). more info >> |
|
| Wednesday, November 30, 2016 |
|
|
エーザイ、第39回サンアントニオ乳がんシンポジウムでエリブリンに関する最新データを発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2016年12月6日から10日まで米国サンアントニオで開催される「第39回サンアントニオ乳がんシンポジウム（San Antonio Breast Cancer Symposium： SABCS2016）」において、当社が創製したエリブリンメシル酸塩（ハリコンドリン系微小管ダイナミクス阻害剤、製品名：「ハラヴェン(R)」）に関する最新の臨床試験データを発表することをお知らせします。 more info >> |
|
|
エーザイ、第70回米国てんかん学会議にてペランパネルおよびルフィナミドに関する最新データを発表 |
| エーザイ株式会社は、2016年12月2日から6日まで米国ヒューストンで開催される「第70回米国てんかん学会議（American Epilepsy Society：AES2016）」において、抗てんかん剤ペランパネル（製品名「フィコンパ(R)」、英名「Fycompa(R)」）、およびルフィナミド（製品名「イノベロン(R)」、米国製品名「Banzel(R)」）に関する最新データを発表しますのでお知らせします。 more info >> |
|
| Friday, November 18, 2016 |
|
|
エーザイ、早期アルツハイマー病を対象としたBACE阻害剤「E2609」の開発について |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の経口BACE（βサイト切断酵素）阻害剤「E2609」の開発について、米国医薬食品局（FDA）よりファストトラック指定（Fast Track designation）を受領しましたのでお知らせします。 more info >> |
|
|
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. FDA has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. more info >> |
|
| Monday, November 14, 2016 |
|
|
エーザイ、2016年 医薬品アクセス貢献度調査（ATMインデックス）の結果について |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、2016年 医薬品アクセス貢献度調査（Access to Medicine Index）において、当社の医薬品アクセスを推進する取り組みが高く評価され、グローバル大手製薬企業の中で11位にランキングされたことをお知らせします。 more info >> |
|
| Friday, November 4, 2016 |
|
|
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer |
| Eisai Co., announced today that its in-house developed anticancer agent Halaven has been recommended by the U.K. National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease in NICE's Final Appraisal Determination (FAD). more info >> |
|
|
|
|
